Thomas Sellers, former director of Moffitt Cancer Center, has filed a lawsuit against his former institution, claiming defamation and tortious interference with a business relationship.
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
European Medicines Agency accepted the Marketing Authorization Application for tucatinib, in combination with trastuzumab and capecitabine, for the treatment of adult patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least two prior anti-HER2 treatment regimens.
European Medicines Agency validated the marketing authorization application for belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Committee for Medicinal Products for Human Use Jan. 30 adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ruxience , intended for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and Pemphigus vulgaris.
FDA and the Federal Trade Commission signed a joint statement Feb. 3 on enhanced collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products.
Fewer than half of Americans recognize that drinking alcohol, diets high in red meat, diets low in vegetables, fruits and fiber and insufficient physical activity all have a clear link to cancer development, according to the American Institute for Cancer Research's ninth Cancer Risk Awareness Survey.
In the first comparative clinical trial of lung cancer screening decision aid versus standard educational information, researchers from MD Anderson Cancer Center demonstrated that a decision aid delivered through tobacco quitlines effectively reaches a screening-eligible population and results in informed decisions about lung cancer screening.
A study at MD Anderson Cancer Center showed that circulating tumor cells, a form of liquid biopsy, was independently associated with melanoma relapse, suggesting CTC assessment may be useful in identifying patients at risk for relapse who could benefit from more aggressive therapy following primary treatment.
